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Digoxin, a plant-derived cardiac glycoside, is the most widely used drug in the treatment of heart disease and is currently the fifth most commonly prescribed medication in the US [I] . The discovery of endogenous counterparts of digoxin in mammals has prompted substantial interest in identifying the structure, function, and metabolism of these digitalis-like ligands. Digoxin-like immunoreactive factor (DLIF), an endogenous steroidlike compound, was first identified as a result of its crossreactivity with anti-digoxin antibodies [2, 3] .3 Considerable evidence suggests that DLIF and ouabain-like factor may be linked in a manner analogous to those of the plant-derived cardenolide counterparts, digoxin [4] and ouabain [5] , to modulation of Na,K-ATPase activity [6] . Control of sodium-pump activity is believed to be an underlying mechanism in the pathophysiology of several diseases, including cardiovascular, neurological, renal, and metabolic disorders [6, 7] . Reports show that concentrations of DLIF in blood are increased relative to healthy subjects in a variety of clinical conditions, including renal failure [8, 9] , hepatic failure [10] , and pregnancy [ii] , and in neonates [12, 13] . Increased concentrations of DLIF in serum are also found in patients with pregnancy-induced hypertension [14, 15] , essential hypertension [16] , and diabetes-related hypertension [17] . The presence of immunoreactive factors in serum also causes discrepancies and inaccuracies in the therapeutic drug monitoring of patients undergoing digitalis therapy [3, 18] . These findings all underscore the importance of characterizing the molecular structure and metabolism of endogenous factors with digitalis-like properties. Cardiac glycosides possess three structural features important in stabilizing their interaction with the sodium pump. These features include a characteristic five-ring structure (aglycone), to which is attached a series of linearly linked sugar residues (three digitoxoses, in the case of digoxmn) extending from the aglycone C-3 position (see Fig. 1 ). The aglycone portion of the glycoside consists of a steroid skeleton with an unsaturated lactone ring attached at position C-17. The chemical state of the lactone ring plays a central role in the structurefunction relation of cardiac glycosides [19] . Although DLIF has [20] . The characteristics include similar molecular masses (-781 Da), similar ultraviolet (T.JV) absorbance spectra (but with DLIF maximum at 216 nm; digoxin at 220 nm), similar chromatographic elution and patterns of deglycosylation under most HPLC conditions, and reactivity with anti-digoxin antibodies (l03-fold lower apparent molar immunoreactivity than digoxin). Recent evidence from our laboratory has identified deglycosylated congeners of DLIF (analogous to the digoxin counterparts digoxigenin, monodigitoxosides, and bisdigitoxosides), and two less-polar, aglycone DLIF species [21] . DLIF is, however, more susceptible to acid hydrolysis of its sugars than is digoxin with respect to the type and concentration of acid and the incubation time and temperature of the hydrolysis [20] . One very important structural aspect that has not been explored is the possible existence of an endogenous DLIF with a reduced lactone ring (i.e., a dihydro-DLIF counterpart to dihydrodigoxin).
Digoxin
Such a molecule would be a viable candidate as a precursor in DLIF metabolism, particularly if oxidation of the reduced lactone ring of dihydrodigoxin to form digoxin were shown to be induced by cellular microsomes.
In this study we demonstrate the existence of a dihydro-DLIF in bovine adrenal cortex and in human serum. We also show a cytochrome P-450-mediated biotransformation of dihy- Tissue preparation. Bovine adrenal glands were obtained from Pel-Freeze Biologicals (Rogers, AR) and processed as previously described [22] . All tissues were maintained at 4 #{176}C during homogenization (dissection, extraction, centrifugation). Other steps were performed at room temperature (22-25 #{176}C) . Briefly, the cortices were separated from medulla, sliced (3-mm-thick sections), chopped, and homogenized in 2 mL of deionized H2O (dH2O) per gram of cortex. The homogenate was centrifuged twice at 34 000g for 30 mm at 4 #{176}C; the pellet from the first cycle was resuspended in dH2O (1 mL/g cortex).
Protein precipitation. Protein was precipitated by incubating the supernate with sulfosalicylic acid (SSA; 10 g/L) at room temperature for 60 s with continuous stirring, followed immediately by adding an excess amount of CaCO3 until the p!-I increased and remained at 5.2 (the pH of the normal adrenal cortex starting homogenate). This extract was then centrifuged at 80 000 g for 10 mm at 4 #{176}C, followed by vacuum filtration with two layers of filter paper (no. 1; Whatman, Clifton, NJ).
Solid-phase extraction.
The C18 reversed-phase Sep-Pak solidphase extraction cartridge (Vac 3 cc) was primed with one volume of CH,CN followed by two volumes of dH2O. The protein-free supernate was passed through the cartridge at a rate of 1 mL/min. The cartridge was then washed with 2-3 volumes of dH2O and eluted with 20 mL of 600 mL/L CH3CN in in mammals dH2O. The CH3CN in the eluates was removed by evaporation to dryness, after which the residue was reconstituted in dH2O and filtered through 0.22-.tm Whatman polyvinylidene fluoride.
Reversed-phase HPLC. The reconstituted Sep-Pak eluate was chromatographed on a HPLC equipped with a reversedphase -Bondapak column (3.9 X 300 mm, 10-pm particle size) and a 996 photodiode array detector to monitor the UV spectra. Initially, a linear CH3CN:H7O gradient (200-800 mL/L over 30 mm) was used to separate DLIF from other steroids. Typically, 1-mL (1-mm) fractions were collected during each chromatographic run with a Waters fraction collector from Millipore
Corp. (Milford, MA). All fractions were evaporated, reconstituted in 1 mL of dH2O, and measured by digoxin RIA before any further analysis.
The concentrated pools of DLIF (eluting at 25 mm) were further chromatographed on an isocratic 390 mL/L CH3CN mobile phase for 10 mm. Twenty fractions (0.5 mL/30 s) were collected, evaporated, reconstituted in H20, and measured by digoxin RIA. The peaks of interest (eluting at 5-6.5 mm) were rechromatographed in the same isocratic mode for additional purification.
The dihydro-DLIF and DLIF species were separated by modifying a previously reported HPLC procedure [23] . We used a Rainin (Woburn, MA) C18 Microsorb-MV colunm (4.6 X 250mm, 3 aim) and an isocratic mobile phase of dichlo- 
Purification
of DLIF from human serum. Digoxin-free freshfrozen human serum was obtained from the American Red Cross, Louisville, KY. Serum was treated with SSA at a final concentration of 10 gIL, vortex-mixed, and centrifuged for 2 mm at 9500g. We applied the entire supernate to a primed C18 reversed-phase Sep-Pak extraction cartridge. The cartridge was then washed with 3 mL of H2O and eluted with 2 mL of 1000 mL/L CH3CN. The subsequent chromatographic purification steps are the same as for the adrenal cortex preparation.
Digoxin-like immunoreactivity.
DLIF was measured by competitive displacement of '251-labeled digoxin from polyclonal digoxin-specific antibodies relative to digoxin calibrators as described elsewhere [24] . The calibrators, digoxin dissolved in human serum, ranged in concentration from 25 to 2000 ng/L. The polyclonal antisera and isotope-labeled digoxin for the assay were obtained from DuPont-New England Nuclear.
Dihydrodigoxin

ELISA.
Dihydrodigoxin-like immunoreactivity was measured with an ELISA involving a polyclonal dihydrodigoxmn antibody [25] . The assay was based on the competitive binding of free and alkaline phosphatase-coupled dihydrodigoxin.
The presence of dihydrodigoxmn in the sample 
Molar absorptiviiy and concentration of DLIF and dihydro-DLIF.
At their respective maximum absorbance wavelengths, we assumed that the molar absorptivity of DLIF and dihydro-DLIF would be comparable with those of digoxin and dihydrodigoxin, respectively. By using the percentage cross-reactivities of DLIF and dihydro-DLIF obtained by digoxmn-RIA or dihydrodigoxin-ELISA, respectively, the apparent molar-immunoreactive concentration of both molecules was determined.
Preparation of adrenocortical microsomes. Bovine adrenal cortex microsomes
were isolated by a modification of a previously described method [26] DLIF and dihydro-DLIF were isolated from 1200 g of bovine adrenal cortex ( isolates from bovine adrenals and human serum (see Fig. 2B and C), one with a maximum absorbance at 196 nm (eluting at 5-5.5 mm) and the other at 216 nm (eluting at 6-6.5 mm).
Immunoreactivitywith specific antibodies to dihydrodigoxin and digoxin. Additional chromatography of these two distinct molecules was accomplished by combining fractions 5 through 6.5 mm from the 390 mL/L CH3CN separation and then eluting with a four-solvent isocratic gradient (DIMH). Using two specific antibodies, one raised to digoxin [24] and the other to dihydrodigoxin [25] , we measured immunoreactivities of the eluted fractions (Fig. 3A) . Note that two distinct immunoreactive peaks, each reacting with one specific antibody, are separated by -1.5 mm. The molecule reacting with antibodies to dihyrodigoxmn and eluting at 26 mm we refer to as dihydro-DLIF. DLIF eluted at 27.5 mm as measured by digoxmn RIA. We observed the same elution pattern for dihydrodigoxin and digoxin (data not shown). The UV spectra of the two peaks in Fig. 3A were remarkably similar to those of dihydrodigoxin (maxima at 196 nm) and DLIF (maxima at 216 nm) relative to digoxmn (maxima at 220) (Fig. 3B) [4, 29] . The 196-nm of dihydro-DLIF is consistent with the presence of a chemically reduced (saturated) lactone ring as shown in Fig. 1 . Table 1 summarizes the molar absorptivities (at each Am5,c)determined by relating mass or immunoreactivity for digoxin and dihydrodigoxin, and for DLIF and dihydro-DLIF, respectively. Assuming similar molar absorption ratios between DLIF and digoxmn and between dihydro-DLIF and dihydrodigoxin (at the respective Am values), the actual amounts of DLIF and dihydro-DLIF in the adrenal tissue extracts are 103 and 540 pmol per gram of cortex, respectively. This calculation assumes comparable extraction efficiencies for both species. Given these assumptions and the concentrations shown in Fig. 4 , the dihydro-DLIF-to-DLIF ratio is -5.3 in adrenal cortex and -0.38 in human serum. Ratio like immunoreactivity in all incubations at time zero (except the mixtures containing no dihydrodigoxmn) could be attributed to the approximate 1-2% cross-reactivity of dihydrodigoxin with the anti-digoxin antibody. The incubation mixtures containing NADPH as cofactor measured 445% more digoxin-like immunoreactivity after 3 h of incubation compared with the baseline at 0 h of incubation.
Concentrations of DLIF and dihydro-DLIF.
In similar experiments, we found no detectable biotransformation of digoxin to dihydrodigoxin. Furthermore, increasing the amount of NADPH (from 1 to 3 mmolJL) in the incubations led to an increase in the amount of digoxmn-like immunoreactivity generated over 6 h (1591 ± 259 at time zero, 3073 ± 344 at 3 h, and 3369 ± 152 pmollL digoxin equivalents at 6 h; mean ± SD for three experiments). No appreciable digoxin-like mmmunoreactivity was generated from dihydrodigoxmn when other pyridmne nucleotides (NADP, NADH, or NAD) were used as cofactors. Also, incubation mixtures without microsomes or dihydrodigoxin or cofactors did not generate appreciable amounts of digoxin-like immunoreactivity. Using a NADPH generating system (glucose 6-phosphate dehydrogenase, NADP, and glucose 6-phosphate),
we also observed generation of digoxin-like immunoreactivity (300%) after 5 mm of incubation (data not shown).
Discussion
In this study we demonstrate the existence of a new molecular form of DLIF (a dihydro-DLIF) analogous to dihydrodigoxin. Three lines of evidence are consistent with the presence of a dihydro-DLIF in bovine adrenal cortex and in human serum: chromatographic mobilities, UV absorption spectra, and crossreactivity with specific antibodies. We also demonstrate a cytochrome P-450-mediated biotransformation of dihydrodigoxin (reduced lactone ring) to a digoxin-like immunoreactive species (oxidized lactone ring) by microsomal components isolated from bovine adrenal cortex.
It is not surprising that the presence of this new DLIF Quantities of DLIF and dihydro-DLIF were obtained by assuming the molar immunoreactivities given in Table 1 molecule; thus this new species was not detected during previous investigation [4] . The DIMH-HPLC method (Fig. 3A) is capable of resolving digoxin from dihydrodigoxin and hence was able to separate DLIF from its chemically reduced counterpart, dihydro-DLIF.
The relative elution times of dihydro-DLIF (reduced form) and DLIF (oxidized form) were almost identical to the elution positions of dihydrodigoxin and digoxin, respectively.
The UV spectra of the endogenous pair, DLIF and dihydro-DLIF, from isolates of both bovine adrenals and human serum are similar to those of the respective plant cardiac glycosides. The Ama,, for digoxin and DLIF are 220 nm and 216 nm, respectively, whereas the reduced forms of these molecules have maximum absorbances at 196 nm. Remarkably, the findings for Ama,, of dihydro-DLIF are consistent with a lactone ring being reduced with two hydrogens and associated with the same UV shift (Fig. 3B) [32] .
To further characterize the presence of a dihydro-DLIF, we used an ELISA specific for dihydrodigoxin.
The two antibodies (anti-digoxin and anti-dihydrodigoxin) have low cross-reactivity with their alternate antigens (<2%) and with commonly identified endogenous steroids (<3%). These antibodies possess significant reaction sensitivities to modifications of the lactonering portion of digoxin and dihydrodigoxin [25, 31] . The ELISA data clearly showed a separate immunoreactive peak eluting from the HPLC that was not "digoxin-like" but was "dihydrodigoxin-like" and correlated in relative elution position with the absorbance spectra characteristic of a cardenolide with a reduced lactone ring (Figs. 2B and C and 3B).
The assumption of equivalent molar absorptivity at their respective absorbance maxima, DLIF at 216 nm and digoxin at 220nm, although a first-order approximation, can be used to estimate the molar concentration of each factor [4] . When applied to dihydro-DLIF and dihydrodigoxin (at 196 nm), our findings suggest that dihydro-DLIF is -2600 times less reactive with the dihydrodigoxin antibody than is dihydrodigoxin ( Table  1) tissue but a much lower ratio (0.38) in serum (Fig. 4) . This is an interesting observation because if dihydro-DLIF is a precursor substrate for biotransformation to DLIF in adrenals, then one might expect higher concentrations of the precursor substrate to accommodate enzymatic regulation of DLIF for secretion into the blood. The ratio of dihydro-DLIF to DLIF in serum may explain not only changes in extent of protein binding during pathology [24] , but also differences in measured values of DLIF by the many different immunoassays available for measuring digoxin [33] . Our findings ( Table 1 ) also suggest that DLIF and dihydro-DLIF exist in vivo at considerably higher concentrations than those measured by immunoreactivity with digoxin or dihydrodigoxin calibrators. We have previously reported the homology of DLIF isolated from bovine adrenal cortex and from human serum [34] . Now, the similarity of both "dihydro-DLIF" and DLIF in both tissue sources as to their cross-reactivity, UV spectra, and chromatographic mobility, as well as their different molar ratios (5.3:1 and 0.38:1 molar ratio in the adrenal cortex and in serum, respectively; see Fig. 4 ) prompted the hypothesis that these two molecular species may be metabolically linked in the adrenal gland. The metabolism of dihydrodigoxrn to a digoxin-like immunoreactive substance by microsomes prepared from bovine adrenal cortex provides supportive evidence to that hypothesis. The need for NADPH as cofactor for this metabolism suggests that oxidation of the lactone ring is mediated by a combined cytochrome P-450 and NADPH-dependent reductase system. Because of the striking similarity in the structures of digoxin and DLIF [4] , dihydro-DLIF and dihydrodigoxin could both be substrates for the same enzyme responsible for such oxidation. Fig. 5 indicates that the incubation mixtures with no dihydrodigoxin added showed negligible amounts of digoxmn-like immunoreactivity at time zero; however, they generated up to 1000 pmolIL digoxmn-like immunoreactivity after 3 h of incu-in mammals bation, but only in the presence of both NADPH and adrenal cortex microsomes combined. This suggests the generation of immunoreactivity from an endogenous precursor such as a dihydro-DLIF, which may have copurified with the microsomes from the adrenal cortex.
The discovery of a new DLIF species with a chemically modified lactone ring suggests the possibility of endogenous metabolic transformation of DLIF. Our findings indicating a dihydro-DLIF congener of DLIF in mammalian tissue should be taken in context with what is known about the metabolism of digoxin. The metabolism of digoxm in mammals has been described as involving three principal types of modifications: sequential deglycosylations of digoxin (primarily from acid hydrolysis in the stomach), conversion of digoxin to not-yetwell-defined less-polar epoxide structures [35] , and conversion of digoxin to dihydrodigoxin by reduction of the lactone ring. The formation of dihydrodigoxin from digoxin in patients has been attributed to the bacterial action of Eubacterium lentum within the gastrointestinal tract [36, 37] . Most interestingly, in vivo conversion of dihydrodigoxmn to digoxin has not, to our knowledge, been reported. These findings now raise intriguing possibilities concerning the metabolism of DLIF in mammalian tissue, particularly in the adrenal cortex where DLIF is believed to be stored, secreted, and presumably synthesized [4] .
The oxidation/reduction state of the lactone ring on digitalis and related cardenolides plays a central role in their interaction with the Na,K-ATPase receptor [19] . Although dihydrodigoxin is considered biologically inactive as a cardiac glycoside, recent evidence suggests that it has binding affinities comparable with those of digoxin for binding to specific isoforms of Na,KATPase [38] . These findings, taken with those of the present study, suggest the possibility that endogenous DLIF and its related congeners may also interact preferentially with the individual isoforms of Na,K-ATPase. Our study demonstrates the existence of a previously unrecognized naturally occurring dihydro-DLIF in adrenal tissues and serum. The importance of this discovery lies in its suggestion of a likely metabolic link with DLIF in the adrenal gland, and provides a possible metabolic route for the formation and secretion of DLIF into the circulation in mammals.
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